Serum Institute, CII to work together for expansion of COVID vaccination in small towns, rural areas

"Our partnership with CII will be a good way to close the gaps, as there is plenty of supply of Covishield available for distribution," Poonawalla said.

Published On 2021-08-02 05:30 GMT   |   Update On 2021-08-02 12:41 GMT
Advertisement

New Delhi: Industry chamber CII on Friday said it has entered into an agreement with Serum Institute of India (SII) to accelerate COVID vaccination in small towns and rural areas.

The chamber said the partnership with Serum Institute will help catalyze industry participation to reach out to communities at large.

"Overall, industry has been playing a responsible part in ensuring vaccination of workers and their families, but clearly given the scale and urgency of the vaccination program, we can complement and supplement the efforts of the government in this pivotal mission for the nation," CII President T V Narendran said in a statement.

Advertisement

On the development, Serum Institute of India CEO Adar Poonawalla said it is essential that all stakeholders work together towards carrying out the inoculations.

"Our partnership with CII will be a good way to close the gaps, as there is plenty of supply of Covishield available for distribution," Poonawalla said.

As part of the pan-India vaccine demand aggregation exercise, CII undertook a survey with response from over 3,000 companies in 196 cities.

Read also: Serum Institute to begin Sputnik V production in September

"This identified a requirement of over 7 million single dose vaccines. As of July 23, 2021, a total of 34,75,301 (3.4 million) single doses have been administered through 430 camps held across the country by the CII and the CII Foundation," it added.

To further scale up the efforts, CII said it is now mapping the vaccination need requirement state-wise and setting up vaccination camps along with its members focusing on reaching Tier 2/3 cities and rural areas.

Read also: Serum Institute gets expert panel nod to phase 2, 3 trial of Covovax for 2-17 years old



Tags:    
Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News